Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX) said Friday their jointly developed drug icotrokinra largely met its primary endpoint of significant skin clearance in a phase 3 study of adults and adolescents with moderate or greater plaque psoriasis on high-impact skin areas.
The 16-week study showed 57% of patients treated with icotrokinra showed clear or almost clear skin compared with 6% for those receiving a placebo, the companies said.
The drug also showed a "favorable" safety profile comparable to the placebo, the companies said.
Protagonist said it expects to submit a new drug application for icotrokinra with the US Food and Drug Administration this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.